Details of the Metabolic Reaction (MR)

General Information of This Metabolic Reaction (MR) (ID: MR000904)
Formula Reactant Efavirenz Product Efavirenz metabolite M5
Reactant Info Product Info
Metabolic Type Oxidation - Hydroxylation
Other MR(s) Related to The Reactant of This MR
Other MR(s) That Metabolize The Reactant of This MR
MR ID Reactant Product MR Type Related Drug REF
MR000903 Efavirenz 8-hydroxy-efavirenz Oxidation - Hydroxylation Efavirenz [1], [2], [3], [4]
MR000905 Efavirenz Efavirenz metabolite M2 Conjugation - Conjugation Efavirenz [5]
Other MR(s) Related to The Product of This MR
Other MR(s) That Metabolize The Produtc of This MR
MR ID Reactant Product MR Type Related Drug REF
MR000901 Efavirenz metabolite M5 Efavirenz metabolite M6 Conjugation - Conjugation Efavirenz [5]
MR000902 Efavirenz metabolite M5 Efavirenz metabolite M7 Conjugation - Conjugation Efavirenz [5]
References
1 Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital. J Clin Pharmacol. 2004 Nov;44(11):1273-81.
2 Biotransformation of Efavirenz and Proteomic Analysis of Cytochrome P450s and UDP-Glucuronosyltransferases in Mouse, Macaque, and Human Brain-Derived In Vitro Systems. Drug Metab Dispos. 2023 Apr;51(4):521-531. doi: 10.1124/dmd.122.001195.
3 Liver Cirrhosis Affects the Pharmacokinetics of the Six Substrates of the Basel?Phenotyping Cocktail Differently. Clin Pharmacokinet. 2022 Jul;61(7):1039-1055. doi: 10.1007/s40262-022-01119-0.
4 Instability of Efavirenz Metabolites Identified During Method Development and Validation. J Pharm Sci. 2021 Oct;110(10):3362-3366. doi: 10.1016/j.xphs.2021.06.028.
5 Clinical pharmacokinetics and drug-drug interactions of Elbasvir/Grazoprevir. Eur J Drug Metab Pharmacokinet. 2018 Oct;43(5):509-531.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.